Frankfurt - Delayed Quote EUR

HLS Therapeutics Inc. (74D.F)

Compare
2.5200
+0.0200
+(0.80%)
At close: January 10 at 8:06:27 AM GMT+1
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
56,940.0000
63,074.0000
61,467.0000
60,009.0000
56,109.0000
Cost of Revenue
8,845.0000
7,624.0000
4,981.0000
3,972.0000
3,625.0000
Gross Profit
48,095.0000
55,450.0000
56,486.0000
56,037.0000
52,484.0000
Operating Expense
49,741.0000
65,799.0000
69,983.0000
62,321.0000
64,571.0000
Operating Income
-1,646.0000
-10,349.0000
-13,497.0000
-6,284.0000
-12,087.0000
Net Non Operating Interest Income Expense
-9,901.0000
-8,398.0000
-7,260.0000
-6,912.0000
-5,985.0000
Other Income Expense
-6,423.0000
-9,056.0000
-2,965.0000
1,388.0000
1,773.0000
Pretax Income
-17,970.0000
-27,803.0000
-23,722.0000
-11,808.0000
-16,299.0000
Tax Provision
4,063.0000
-272.0000
-124.0000
1,309.0000
-968.0000
Net Income Common Stockholders
-22,033.0000
-27,531.0000
-23,598.0000
-13,117.0000
-15,331.0000
Diluted NI Available to Com Stockholders
-22,033.0000
-27,531.0000
-23,598.0000
-13,117.0000
-15,331.0000
Basic EPS
-0.69
-0.85
-0.73
-0.41
-0.48
Diluted EPS
-0.69
-0.85
-0.73
-0.41
-0.48
Basic Average Shares
31,914.8400
32,263.2970
32,432.8510
32,184.0760
31,713.5920
Diluted Average Shares
31,914.8400
32,263.2970
32,432.8510
32,184.0760
31,713.5920
Total Operating Income as Reported
--
--
--
-6,284.0000
-12,087.0000
Total Expenses
58,586.0000
73,423.0000
74,964.0000
66,293.0000
68,196.0000
Net Income from Continuing & Discontinued Operation
-22,033.0000
-27,531.0000
-23,598.0000
-13,117.0000
-15,331.0000
Normalized Income
-16,573.4500
-18,563.5959
-20,648.4987
-14,137.1800
-16,519.9309
Interest Income
496.0000
350.0000
57.0000
44.0000
322.0000
Interest Expense
10,397.0000
8,748.0000
7,317.0000
6,956.0000
6,307.0000
Net Interest Income
-9,901.0000
-8,398.0000
-7,260.0000
-6,912.0000
-5,985.0000
EBIT
-7,573.0000
-19,055.0000
-16,405.0000
-4,852.0000
-9,992.0000
EBITDA
16,757.0000
12,884.0000
17,997.0000
25,412.0000
23,194.0000
Reconciled Cost of Revenue
8,845.0000
7,624.0000
4,981.0000
3,972.0000
3,625.0000
Reconciled Depreciation
24,330.0000
31,939.0000
34,402.0000
30,264.0000
33,186.0000
Net Income from Continuing Operation Net Minority Interest
-22,033.0000
-27,531.0000
-23,598.0000
-13,117.0000
-15,331.0000
Total Unusual Items Excluding Goodwill
-6,423.0000
-9,056.0000
-2,965.0000
1,388.0000
1,264.0000
Total Unusual Items
-6,423.0000
-9,056.0000
-2,965.0000
1,388.0000
1,264.0000
Normalized EBITDA
23,180.0000
21,940.0000
20,962.0000
24,024.0000
21,930.0000
Tax Rate for Calcs
0.0002
0.0000
0.0000
0.0003
0.0001
Tax Effect of Unusual Items
-963.4500
-88.5959
-15.4987
367.8200
75.0691
12/31/2020 - 11/19/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers